Matches in SemOpenAlex for { <https://semopenalex.org/work/W2143973265> ?p ?o ?g. }
Showing items 1 to 83 of
83
with 100 items per page.
- W2143973265 endingPage "722" @default.
- W2143973265 startingPage "708" @default.
- W2143973265 abstract "Psoriasis is a multifactorial autoimmune skin disorder based on irregularities of the T- cell function. The abnormal keratinocyte hyper proliferation in psoriasis arises due to the activation of T-cells which produces rich amount of arachidonic acid leads to generation of various proinflammatory mediators like PGs, LTs, cytokines and adhesion molecules via MAPK/AP-1, EARK1/2 and protein kinase – C (PKCs) activation pathways. Incorporation of naturally occuring bioactives like, omega (ω) - 3 fatty acids (i.e., EPA and DHA) in a dose dependent manner results in inhibition of various pro-inflammatory mediators and metabolization of EPA and DHA leads to dampening of inflammation and higher resolution of the skin abnromalities. These all due to the promotion of the synthesis of ω-3 PUFA-derived lipid mediators viz namely resolvins and protectins. These have been widely used alone or in combination with other drugs in the treatment of psoriasis. Despite of their meritorious visages, the use of these bioactives is associated with several hiccups like higher unstability and vulnerable to degradation due to lipid peroxidation, poor and incosistent bioavilability by oral and topical administration. The potential use of nanomedicines in the delivery of such bioactives has gained wider attention owing to their promising bioavailability enhancement characteristics, improved stability and better efficacy. The present review gives an extensive account on ω-3 fatty acids (EPA and DHA) starting from seedling to apex, including biosynthesis, metabolites, and its mechanism of action in psoriasis. Moreover, barriers in the effective delivery of ω-3 fatty acids and how nanomedicines can be fit in the scope of its therapeutic delivery in psoriasis have also been addressed. Despite numerous advantages, application of EPA-DHA as ω-3 fatty acids therapeutics in the management of psoriasis are still at an initial stage. Nanomedicines approach to achieve high bioavailable delivery with safety and stability of ω-3 fatty acids showing the promising area for the future in psoriasis management. Keywords: Omega 3 fatty acids, psoriasis, resolvins, protectins, patents, antioxidants, nanomedicines." @default.
- W2143973265 created "2016-06-24" @default.
- W2143973265 creator A5028490369 @default.
- W2143973265 creator A5034615251 @default.
- W2143973265 creator A5041945418 @default.
- W2143973265 creator A5044356237 @default.
- W2143973265 creator A5053036026 @default.
- W2143973265 creator A5061244523 @default.
- W2143973265 creator A5085657354 @default.
- W2143973265 creator A5087908803 @default.
- W2143973265 date "2013-05-01" @default.
- W2143973265 modified "2023-10-18" @default.
- W2143973265 title "Omega – 3 Fatty Acids as Pharmacotherapeutics in Psoriasis: Current Status and Scope of Nanomedicine in its Effective Delivery" @default.
- W2143973265 doi "https://doi.org/10.2174/1389450111314060011" @default.
- W2143973265 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23531113" @default.
- W2143973265 hasPublicationYear "2013" @default.
- W2143973265 type Work @default.
- W2143973265 sameAs 2143973265 @default.
- W2143973265 citedByCount "29" @default.
- W2143973265 countsByYear W21439732652013 @default.
- W2143973265 countsByYear W21439732652014 @default.
- W2143973265 countsByYear W21439732652015 @default.
- W2143973265 countsByYear W21439732652016 @default.
- W2143973265 countsByYear W21439732652017 @default.
- W2143973265 countsByYear W21439732652018 @default.
- W2143973265 countsByYear W21439732652019 @default.
- W2143973265 countsByYear W21439732652020 @default.
- W2143973265 countsByYear W21439732652021 @default.
- W2143973265 countsByYear W21439732652022 @default.
- W2143973265 countsByYear W21439732652023 @default.
- W2143973265 crossrefType "journal-article" @default.
- W2143973265 hasAuthorship W2143973265A5028490369 @default.
- W2143973265 hasAuthorship W2143973265A5034615251 @default.
- W2143973265 hasAuthorship W2143973265A5041945418 @default.
- W2143973265 hasAuthorship W2143973265A5044356237 @default.
- W2143973265 hasAuthorship W2143973265A5053036026 @default.
- W2143973265 hasAuthorship W2143973265A5061244523 @default.
- W2143973265 hasAuthorship W2143973265A5085657354 @default.
- W2143973265 hasAuthorship W2143973265A5087908803 @default.
- W2143973265 hasConcept C164027704 @default.
- W2143973265 hasConcept C180899940 @default.
- W2143973265 hasConcept C181199279 @default.
- W2143973265 hasConcept C185592680 @default.
- W2143973265 hasConcept C203014093 @default.
- W2143973265 hasConcept C2776914184 @default.
- W2143973265 hasConcept C2778078955 @default.
- W2143973265 hasConcept C2780564577 @default.
- W2143973265 hasConcept C55493867 @default.
- W2143973265 hasConcept C71924100 @default.
- W2143973265 hasConcept C98274493 @default.
- W2143973265 hasConceptScore W2143973265C164027704 @default.
- W2143973265 hasConceptScore W2143973265C180899940 @default.
- W2143973265 hasConceptScore W2143973265C181199279 @default.
- W2143973265 hasConceptScore W2143973265C185592680 @default.
- W2143973265 hasConceptScore W2143973265C203014093 @default.
- W2143973265 hasConceptScore W2143973265C2776914184 @default.
- W2143973265 hasConceptScore W2143973265C2778078955 @default.
- W2143973265 hasConceptScore W2143973265C2780564577 @default.
- W2143973265 hasConceptScore W2143973265C55493867 @default.
- W2143973265 hasConceptScore W2143973265C71924100 @default.
- W2143973265 hasConceptScore W2143973265C98274493 @default.
- W2143973265 hasIssue "6" @default.
- W2143973265 hasLocation W21439732651 @default.
- W2143973265 hasLocation W21439732652 @default.
- W2143973265 hasOpenAccess W2143973265 @default.
- W2143973265 hasPrimaryLocation W21439732651 @default.
- W2143973265 hasRelatedWork W1504778884 @default.
- W2143973265 hasRelatedWork W1953077261 @default.
- W2143973265 hasRelatedWork W2081221505 @default.
- W2143973265 hasRelatedWork W2136880567 @default.
- W2143973265 hasRelatedWork W2295384369 @default.
- W2143973265 hasRelatedWork W2567066701 @default.
- W2143973265 hasRelatedWork W2791386016 @default.
- W2143973265 hasRelatedWork W4316670316 @default.
- W2143973265 hasRelatedWork W4385980346 @default.
- W2143973265 hasRelatedWork W76176096 @default.
- W2143973265 hasVolume "14" @default.
- W2143973265 isParatext "false" @default.
- W2143973265 isRetracted "false" @default.
- W2143973265 magId "2143973265" @default.
- W2143973265 workType "article" @default.